Beam Therapeutics Inc.
BEAMNASDAQHealthcare● Active
$29.78
+$0.38(+1.29%)
Market Cap$3.1B
P/E Ratio—
52W High$36.44
52W Low$15.6
Beam Therapeutics Inc. (BEAM) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BEAM · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.08B) | ($0.38B) | ($0.13B) | ($0.29B) | ($0.37B) |
| Depreciation & Amort. | $0.02B | $0.02B | $0.02B | $0.01B | $0.01B |
| Stock-Based Comp. | $0.09B | $0.12B | $0.10B | $0.08B | $0.04B |
| Change in Working Capital | ($0.13B) | ($0.11B) | ($0.12B) | $0.25B | $0.11B |
| Net Cash from Operations | ($0.35B) | ($0.35B) | ($0.15B) | $0.02B | ($0.07B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.01B) | ($0.01B) | ($0.03B) | ($0.05B) | ($0.05B) |
| Purchases of Investments | ($1.21B) | ($0.49B) | ($0.98B) | ($1.62B) | ($0.78B) |
| Sales of Investments | $0.85B | $0.68B | $1.09B | $1.20B | $0.53B |
| Net Cash from Investing | ($0.12B) | $0.19B | $0.07B | ($0.46B) | ($0.29B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Net Cash from Financing | $0.48B | $0.01B | $0.28B | $0.11B | $0.76B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.36B) | ($0.36B) | ($0.18B) | ($0.03B) | ($0.11B) |
| FCF Margin %(computed) | -257.65% | -560.77% | -48.43% | -43.37% | -218.11% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Beam Therapeutics Inc. data
About Beam Therapeutics Inc. (BEAM) Cash Flow Statement
Beam Therapeutics Inc. generated operating cash flow of ($0.35B) and free cash flow of ($0.36B) for 2025 — a FCF margin of -257.65%. Capital expenditure was ($0.01B).
Frequently asked questions
BEAM · 4 questionsBeam Therapeutics Inc. generated free cash flow of ($0.36B) for 2025, down 1.1% year-over-year.
BEAM free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10